Kuro Games announced the events and banners for Wuthering Waves version 2.3 Phase 2 (Image via Kuro Games) Kuro Games announced all the events and banners coming with Wuthering Waves 2.3 second phase.

Dive into Sprunki MSI Canon Phase 3, where new characters and immersive soundscapes deepen the narrative. Experience a thrilling evolution of dark themes. Sprunki MSI Phase 3 represents a thrilling ...

In order to expand the application of the PMSM in the field of high-power traction, a robust predictive torque control (R-PTC) strategy for the N-segment three-phase PMSM (N*3-phase PMSM) is proposed ...

Delta-like ligand 3 (DLL3), a Notch signaling regulator overexpressed in 70–80% of SCLC tumors, has emerged as a simultaneous biomarker and therapeutic target. This review aims to synthesize recent ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled nerandomilast “a step forward but not game-changing.” Boehringer revealed ...

Aardvark Therapeutics, Inc. announced progress in its Phase 3 HERO trial for ARD-101, aimed at treating hyperphagia associated with Prader-Willi Syndrome, with data expected in early 2026.

BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a phase 3 enzyme replacement therapy to its pipeline. California-based ...

The preliminary trial results announced Monday are from a Phase 3 test that enrolled 646 adults in the U.S. and Canada who have mild, moderate, or severe OSA and either cannot tolerate CPAP ...

But with promising early results from a phase 3 study in certain patients, the checkpoint inhibitor may have found its place. At a pre-specified interim analysis of Merck’s phase 3 Keynote-B96 ...

Residents of J.P. Nagar have raised serious concerns about the proposed double-decker flyover under Namma Metro Phase 3, warning that its alignment could worsen traffic congestion near the already ...

The company's phase 3 Essence study tested the therapy in patients with moderate hypertriglyceridemia who have or are at risk for atherosclerotic cardiovascular disease (ASCVD ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.